Molecular Characterisation of Appendiceal Cancer

ConditionAppendiceal Cancer

Trial statusRecruiting

Trial phaseNot listed

Trial typeObservational

Biological sexAll

Age18+

SponsorThe Christie NHS Foundation Trust

About this trial

Patients ≥ 18 years old who have been diagnosed with appendiceal cancer with peritoneal metastases, have had cytoreductive surgery, have availability of archival tumour tissue and have consented to our institutional biobank program or have a waiver of consent for deceased patients who have not had the opportunity to provide biobank consent (requested at the time of ethics review). Descriptive analysis of the proportion of genetic mutations identified in appendiceal cancers. This is given by the percentage of pathogenic mutations in the peritoneal metastasis compared to the primary tumour.

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

Patients ≥ 18 years old who have been diagnosed with appendiceal cancer with peritoneal metastases,

have had cytoreductive surgery

have availability of archival tumour tissue

Disqualifiers

None

Trial population

Patients who have been diagnosed with appendiceal cancer with peritoneal metastases

Trial design

Design model

Other

Time perspective

Retrospective

Treatments tested in this trial

Retrospective tissue sample analysis
Other intervention
Acquisition of archival Formalin Fixed Paraffin Embedded (FFPE) human tissue from appendix cancer primary tumour and peritoneal metastases, which are stored in NHS pathology - taken from standard care biopsies.

Treatment groups

100 Participants

are divided into 1 treatment group

Group A: All participants1 intervention

Trial outcomes

Primary outcomes

Characterise the genes of appendiceal cancer.

Descriptive analysis of the proportion of genetic mutations identified in appendiceal cancers. This is given by the percentage of pathogenic mutations in the peritoneal metastasis compared to the primary tumour.

Time frame

2 years

Secondary outcomes

Descriptive analysis in proportions

The descriptive difference in proportion of genetic mutations identified in primary appendiceal tumours compared to mutations in peritoneal metastases. Association between molecular subtypes and categorical variables were measured by Fisher's exact or X2 tests. Associations with continuous variables will be evaluated by Kruskal-Wallis tests or ANOVA. Kaplan-Meier methods will calculate survival outcomes.

Time frame

2 years

Sponsors and contacts

Click on the lead sponsor to view all of their trials.

The Christie NHS Foundation Trust

Lead sponsor

University of Manchester

Collaborator

Source ClinicalTrials.gov

Apply now